-
公开(公告)号：US11306144B2
公开(公告)日：2022-04-19
申请号：US16111064
申请日：2018-08-23
Applicant: Five Prime Therapeutics, Inc.
Inventor： Charles Kaplan , Derrick Houser , Luis Borges , Gloria Brattich , David Bellovin , Felicia Kemp , Majid Ghoddusi , Nels P. Nielson , Kathy Miller , Maike Schmidt
IPC: C07K16/28 , A61K39/395 , A61P35/00 , G01N33/574 , A61K39/00
Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.
-
公开(公告)号：US20200031944A1
公开(公告)日：2020-01-30
申请号：US16497906
申请日：2018-03-29
Applicant: Five Prime Therapeutics, Inc.
Inventor： Susannah D. Barbee , David Bellovin , Luis Borges
IPC: C07K16/28 , A61P35/00 , A61K39/395 , A61K31/7068 , A61K31/337 , A61K47/64 , A61K31/525 , A61K31/513 , A61K31/4745 , A61K31/282
Abstract: Provided herein are methods of treating cancer with a combination of an anti glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR)-antibody and an antibody that binds colony stimulating factor 1 receptor (CSF1R) or with a combination of an anti-GITR antibody and an antibody that binds programmed cell death protein 1 (PD-1).
-
公开(公告)号：US10221244B2
公开(公告)日：2019-03-05
申请号：US15680664
申请日：2017-08-18
Inventor： Brian Wong , Julie Hambleton , Robert Sikorski , Emma Masteller , Kevin Hestir , David Bellovin , Katherine E. Lewis
IPC: C07K16/28 , C07K16/30 , A61K39/395 , A61K39/00
Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
-
公开(公告)号：US09775881B2
公开(公告)日：2017-10-03
申请号：US14890047
申请日：2014-05-22
Inventor： David Bellovin , Kevin Baker , Thomas Brennan , Arundathy Nirmalini Pandite , Bijoyesh Mookerjee , Maurice P. DeYoung , Rakesh Kumar
IPC: A61K38/17 , A61K31/337 , C07K14/71 , C12Q1/68 , G01N33/53 , G01N33/574 , A61K31/519 , A61K31/555 , A61K33/24 , A61K45/06
CPC classification number: A61K38/179 , A61K31/337 , A61K31/519 , A61K31/555 , A61K33/24 , A61K45/06 , C07K14/71 , C07K2319/30 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/574 , G01N33/57496 , G01N2333/49 , G01N2333/50 , G01N2333/503 , G01N2333/515 , G01N2800/52
Abstract: Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.
-
公开(公告)号：US11098103B2
公开(公告)日：2021-08-24
申请号：US16354689
申请日：2019-03-15
Applicant: Five Prime Therapeutics, Inc.
Inventor： Thomas Brennan , David Bellovin , David Busha , Barbara Sennino
IPC: C07K14/705 , A61K38/17 , A61K39/395 , A61K45/06 , C07K16/00 , C07K16/28 , A61K38/00
Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
-
Patent Agency Ranking
公开(公告)号：US20210009697A1
公开(公告)日：2021-01-14
申请号：US16646690
申请日：2018-09-12
Inventor： Katherine E. Lewis , Serena Kimi Perna , Michael Carleton , Ke Xu , Penny Phillips , Dimple Pandya , Brian Wong , Julie Hambleton , Robert Sikorski , Emma Masteller , Kevin Hestir , David Bellovin , Janine Powers , Ernestine Lee
IPC: C07K16/28 , A61K31/7068 , A61K31/513 , A61K39/395 , A61K31/337 , A61K47/69 , A61K47/64 , C12Q1/6886 , A61P35/00
Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
-
公开(公告)号：US20190202921A1
公开(公告)日：2019-07-04
申请号：US16243510
申请日：2019-01-09
Inventor： Brian Wong , Julie Hambleton , Robert Sikorski , Emma Masteller , Kevin Hestir , David Bellovin , Katherine E. Lewis
CPC classification number: C07K16/2866 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/2803 , C07K16/2818 , C07K16/3046 , C07K16/3069 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
-
公开(公告)号：US09765147B2
公开(公告)日：2017-09-19
申请号：US14925534
申请日：2015-10-28
Inventor： Brian Wong , Julie Hambleton , Robert Sikorski , Emma Masteller , Kevin Hestir , David Bellovin , Katherine E. Lewis
CPC classification number: C07K16/2866 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/2803 , C07K16/2818 , C07K16/3046 , C07K16/3069 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
-
公开(公告)号：US20240043542A1
公开(公告)日：2024-02-08
申请号：US18484986
申请日：2023-10-11
Applicant: FIVE PRIME THERAPEUTICS, INC.
Inventor： Charles Kaplan , Derrick Houser , Luis Borges , Gloria Brattich , David Bellovin , Felicia Kemp , Majid Ghoddusi , Nels P. Nielson , Kathy Miller , Maike Schmidt
IPC: C07K16/28 , A61P35/00 , G01N33/574
CPC classification number: C07K16/2827 , C07K16/2818 , A61P35/00 , G01N33/57492 , A61K2039/505
Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.
-
10.发明公开公开(公告)号：US20230192870A1
公开(公告)日：2023-06-22
申请号：US17812592
申请日：2022-07-14
Inventor： Katherine E. Lewis , Serena Kimi Perna , Michael Carleton , Ke Xu , Penny Phillips , Dimple Pandya , Brian Wong , Julie Hambleton , Robert Sikorski , Emma Masteller , Kevin Hestir , David Bellovin , Janine Powers , Ernestine Lee
IPC: C07K16/28 , A61K47/69 , A61K47/64 , A61P35/00 , A61K31/337 , A61K31/513 , A61K31/7068 , A61K39/395 , C12Q1/6886
CPC classification number: C07K16/2866 , A61K47/6929 , A61K47/643 , A61P35/00 , A61K31/337 , A61K31/513 , A61K31/7068 , A61K39/3955 , C07K16/2818 , C12Q1/6886 , A61K2039/507
Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.027 seconds)
